SEERSeer, Inc.
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Seer (SEER) Q2 2026 Earnings Call Transcript Revenue grew to $3.1 million despite academic funding headwinds. | ||
 Seer, Inc. Q2 2026 Earnings Call Summary Moby summary of Seer, Inc.'s Q2 2026 earnings call | ||
Seer Inc (SEER) (Q2 2026) Earnings Call Highlights: Navigating Funding Headwinds While ... Seer Inc (SEER) reaffirms full-year guidance despite a year-over-year revenue dip, bolstered by strong cash reserves, groundbreaking independent validations, and promising AI cancer screening data. | ||
 Seer Q2 Earnings Call Highlights Seer (NASDAQ:SEER) reported second-quarter revenue of $3.1 million, down from $4.1 million a year earlier but up from $2.8 million in the first quarter, as the proteomics company cited continued pressure on academic and government funding and longer sales cycles among some commercial customers. Chi | ||
Sector Update: Healthcare Stocks Gain Late Afternoon Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 2.3% and | MMT Newswires | |